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Abstract
Background: Large-scale whole genome sequencing (WGS) studies promise to revolutionize cancer research by
identifying targets for therapy and by discovering molecular biomarkers to aid early diagnosis, to better determine
prognosis and to improve treatment response prediction. Such projects raise a number of ethical, legal, and social
(ELS) issues that should be considered. In this study, we set out to discover how these issues are being handled
across different jurisdictions.
Methods: We examined informed consent (IC) forms from 30 cancer genome sequencing studies to assess (1)
stated purpose of sample collection, (2) scope of consent requested, (3) data sharing protocols (4) privacy
protection measures, (5) described risks of participation, (6) subject re-contacting, and (7) protocol for withdrawal.
Results: There is a high degree of similarity in how cancer researchers engaged in WGS are protecting participant
privacy. We observed a strong trend towards both using samples for additional, unspecified research and sharing
data with other investigators. IC forms were varied in terms of how they discussed re-contacting participants,
returning results and facilitating participant withdrawal. Contrary to expectation, there were no consistent trends
that emerged over the eight year period from which forms were collected.
Conclusion: Examining IC forms from WGS studies elucidates how investigators are handling ELS challenges posed
by this research. This information is important for ensuring that while the public benefits of research are
maximized, the rights of participants are also being appropriately respected.
Background
The past decade has been characterized by a breathtak-
ing acceleration in genome sequencing technology [1].
W h i l ea tt h eb e g i n n i n go ft h ed e c a d ei tt o o ky e a r st o
sequence the first complete human genome, over 200
human genomes have been sequenced in the past year
alone, and experts predicts that approximately 25,000
will be sequenced by the end of 2011 [2]. One of the
most exciting applications of this new technology is
deciphering the genetic basis of complex diseases [3].
Cancer in particular provides an ideal and noteworthy
focus for this approach. As a highly heterogeneous
genetic disease mainly driven by somatic mutations that
can occur at a multitude of locations, cancer is particu-
l a r l ya m e n a b l et ot h i st y p eo fs t u d y .B ye n a b l i n g
researchers to compare the host genome to that of the
cancer itself, whole genome sequencing (WGS) technol-
ogy promises to not only identify predictors of, and tar-
gets for, therapy, but also discover novel molecular
biomarkers to aid in the early detection of cancer. In
combination, these will likely positively influence prog-
nosis [4]. Consequently, a number of large-scale
research studies using WGS technology to identify
genetic components of cancer have recently been
initiated. Projects such as The Cancer Genome Atlas
and the International Cancer Genome Consortium are
obtaining biological samples from thousands of subjects
around the world in an attempt to catalogue the myriad
genetic and genomic alterations that are critical to carci-
nogenesis. This research raises a number of ethical,
legal, and social (ELS) issues that need to be addressed.
Investigators engaged in large-scale WGS research
projects must consider how to manage issues such as
sample and data sharing, protecting participant privacy
and confidentiality, communicating the risks and bene-
fits of research to participants, returning individual
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research when requested. These issues are common to
the majority of human subject research, but the unpre-
cedented volume of genomic data that is being collected
through WGS, the inherent unpredictability of what this
technology will reveal in comparison to targeted sequen-
cing and the rapid rate at which our interpretive abilities
are advancing obliges us to re-examine these issues in
the context of this research. Our goal in this study
therefore was to perform a qualitative analysis of con-
sent forms in order to discern how investigators cur-
rently engaged in cancer genome sequencing across a
variety of jurisdictions are addressing these issues.
Focusing on cancer genome research enables compari-
son across studies, allowing us to add to knowledge of
current practices, identify similarities and differences,
and determine whether common practices are emerging.
As informed consent (IC) documents are the main vehi-
cle through which information about ELS issues is com-
municated to research participants, we chose to focus
our study on the analysis of these forms. We anticipated
that trends would emerge both across jurisdictions and
over time.
Methods
We obtained contact details for researchers engaged in
cancer genome sequencing by visiting the websites of
large-scale WGS projects, found by doing internet
searches for ‘whole genome sequencing’ and navigating
the website of the National Institute of Health. We also
searched http://Pubmed.gov for papers reporting studies
that involved sequencing whole cancer genomes, using
the key words ‘w h o l eg e n o m es e q u e n c i n g ’ and ‘next-
generation sequencing’ and limiting the searches to
humans only, within the past five years, under the sub-
set ‘cancer’. Additional file 1, Table 1 presents a list of
these studies that is current at the time of publication,
with a succinct summary of their key findings. Our per-
sonal knowledge of ongoing research projects provided
further guidance in this search.
We contacted researchers via email and/or phone. Indi-
viduals were selected on the basis of either being listed
as a primary contact at tissue source sites for large-scale
WGS projects, or as corresponding authors for journal
articles. We explained the details of our research pro-
ject, and requested that the researchers send us tem-
plates of the informed consent documents used by their
institutions or research groups when obtaining tissue
samples for cancer genome sequencing research. It was
explained to potential participants that neither specific
institutions nor individuals would be identified in our
results or discussion. In total 54 researchers were identi-
f i e d .O ft h e s e ,1 2w e r ee x c l u d e do nt h eb a s i so fb e i n g
part of the same research groups as other researchers
on the list. Of the 42 remaining researchers, 30 sent
informed consent documents, giving us a response rate
of 71.4%.
We performed a qualitative thematic analysis on the
IC forms that were received. We assigned each docu-
ment a value under the following headings: (1) stated
purpose of sample collection, (2) scope of consent
requested, (3) data sharing protocols (4) privacy protec-
tion measures, (5) described risks of participation, (6)
subject re-contacting, and (7) protocol for withdrawal.
Values were specific to each heading, and represented
what was stated in the informed consent document in
relation to the topic at hand.
Results
For the 30 informed consent documents obtained, the
country-of-origin breakdown was as follows: one from
Belgium, one from the Netherlands, three from Austra-
lia, three from Canada, three from the UK and nineteen
f r o mt h eU S .T h em o s tr e c e n t l yd a t e df o r mw a sf r o m
May 2011, while the oldest was dated March 2004. Six
of the forms were not dated, while three others were
from 2011, six were from 2010, five were from 2009,
five were from 2008, one was from 2006, and two were
from 2005. The key findings from our thematic analysis,
in summary form, are presented in Table 1.
We divided the IC forms into three categories based
on the described purpose of tissue sample acquisition.
Of the 30 documents obtained, the majority (n = 17)
stated that samples were being collected for the purpose
of cancer genetics research. Six were seeking samples
for the purpose of broader medical research on a parti-
cular system or tissue type. Five were seeking blanket
consent for any type of generalized medical research.
Two forms were templates, in which the purpose of
research was to be filled in upon use.
In addition to the stated purpose of the sample collec-
tion, we identified the scope of the consent that was
being requested. Only two of the documents were seek-
ing consent exclusively for the specific study described.
Six were seeking consent to use the samples collected
for research related to the study at hand, for example
on the same disease, and intended to keep the samples
indefinitely for this purpose. Six documents provided a
choice as to the scope of consent, while sixteen stated
that once obtained, samples might be used for any type
of research at any future date.
The documents discussed not only sharing of samples
with other researchers, but the sharing of data as well.
Eleven of the documents stated that data might be
shared with other researchers who were in some way
affiliated with the project being described, for example
in terms of working with the same organization or on
the same disease. Sixteen of the documents stated that
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Form Source Research
scope
Type of
results
returned
Re-
contacting
choice?
Purpose of
re-contact
Data
sharing
with?
Holder of
coded
data key
Risk of dis-
crimination
discussed?
Scope
of
consent
Right to
withdrawal
2004 UK Genetic basis
of cancer
General
only
No
comment
No
comment
Affiliated
research
PI No Study
only
Consequences
unclear
2005 US A particular
system
General
only
No
comment
No
comment
Affiliated
research
PI Yes Related
Research
Samples
destroyed but
not info that has
been used
2005 Australia General
scientific
research
Individual,
no option
Yes, may re-
contact
Follow-up
info
Any who
apply
Third party No Choice
Provided
Samples
destroyed but
not info that has
been used
2006 US Genetic basis
of cancer
No
comment
No, will re-
contact
Follow up
info and
future
research
Any who
apply
PI Yes Blanket
consent
Samples
destroyed but
not info that has
been used
2008 UK A particular
system
None No
comment
No
comment
Any who
apply
Third party No Blanket
consent
All info removed/
destroyed
2008 US Genetic basis
of cancer
General
only
No, will re-
contact
Follow up
info
Any who
apply
PI Yes Blanket
consent
Samples
destroyed but
not info that has
been used
2008 US General
scientific
research
General
only
No
comment
No
comment
Any who
apply
Identifying
info not
collected
Yes Blanket
consent
No withdrawal
(samples
anonymized)
2008 Canada Genetic basis
of cancer
None No, will re-
contact
Follow up
info
No
comment
Third party Yes Related
research
Consequences
unclear
2009 Canada Genetic basis
of cancer
Individual,
with option
No
comment
No
comment
Affiliated
researchers
PI Yes Study
only
All info removed/
destroyed
2009 Canada Genetic basis
of cancer
No
comment
Yes, may re-
contact
Future
research
Affiliated
researchers
Third party Yes Related
research
Consequences
unclear
2009 Belgium Genetic basis
of cancer
Individual,
with option
No
comment
No
comment
Affiliated
researchers
PI No Blanket
consent
Samples
destroyed but
not info that has
been used
2009 US Genetic basis
of cancer
Individual,
with option
Yes, may re-
contact
Follow up
info
Any who
apply
Identifying
info may
be shared
Yes Choice
provided
Samples
destroyed but
not info that has
been used
2009 US Genetic basis
of cancer
Individual
and
general, no
option
Yes, may re-
contact
Follow up
info and
future
research
Any who
Apply
PI Yes Blanket
consent
Samples
destroyed but
not info that has
been used
2010 US Cancer
research
None Yes, may re-
contact
Follow up
info and
future
research
No
comment
Third party Yes Choice
provided
No comment
2010 US Un-
determined
General
only
No, will re-
contact
Follow up
info
Any who
apply
Third party Yes Blanket
consent
Samples
destroyed but
not info that has
been used
2010 US Genetic basis
of cancer
No
comment
Yes, may re-
contact
Follow up
info
Affiliated
researchers
Third party No Related
research
Samples
destroyed but
not info that has
been used
2010 US Genetic basis
of cancer
None Yes, may re-
contact
Follow up
info
Any who
apply
PI Yes Blanket
consent
Samples
destroyed but
not info that has
been used
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tive data would be placed in secure databases to which
researchers would need to apply in order to gain access.
Three of the documents did not reference data sharing
at all.
Although many of the documents asked for broad
consent and stated fairly liberal data sharing intentions,
all but one (which did not collect identifying
information) of the documents stated that data would
be coded, with personal identifiers removed, and only a
single person or small group of people having access to
keys for linking coded information to specific research
subjects. Although in three cases it was not stated, in
approximately half (n = 13) of the forms the primary
investigator was identified as the person with key access,
while the other half (n = 13) stated that only data bank
Table 1 Summary of Results (Continued)
2010 Netherlands General
scientific
research
None No
comment
No
comment
No
comment
Third party No Blanket
consent
No comment
2010 UK Undetermined General
only
No
comment
No
comment
Any who
apply
Third party Un-
determined
Blanket
consent
Samples
destroyed but
not info that has
been used
2010 Australia Genetic basis
of cancer
Individual
and
general,
with option
Yes, may re-
contact
Follow up
info
Affiliated
researchers
Third party No Related
research
All info removed/
destroyed
2011 US A particular
system
None Yes, may re-
contact
Follow up
info and
future
research
Any who
apply
Third party Yes Choice
provided
Samples
destroyed but
not info that has
been used
2011 US Cancer
research
General
only
No, will re-
contact
Follow up
info
Affiliated
researchers
Identifying
info may
be shared
Yes Blanket
consent
Samples
destroyed but
not info that has
been used
2011 US A particular
system
Individual,
no option
No, will re-
contact
Individual
results
Any who
apply
Third party Yes Choice
provided
Samples
destroyed but
not info that has
been used
2011 US General
scientific
research
General
only
No
comment
No
comment
Affiliated
researchers
Third party Yes Blanket
consent
Samples
destroyed but
not info that has
been used
None Australia Genetic basis
of cancer
Individual,
no option
No, will re-
contact
Individual
results
Any who
apply
PI No Blanket
consent
Samples
destroyed but
not info that has
been used
None US Genetic basis
of cancer
None No, will re-
contact
Follow up
info
Any who
apply
PI Yes Blanket
consent
Samples
destroyed but
not info that has
been used
None US Genetic basis
of cancer
Individual,
with option
No, will re-
contact
Future
research and
individual
results
Affiliated
researchers
PI Yes Blanket
consent
Consequences
unclear
None US General
scientific
research
None No
comment
No
comment
Affiliated
researchers
Third party Yes Choice
provided
Samples
destroyed but
not info that has
been used
None US Genetic
research
Individual,
no option
No, will re-
contact
Follow up
info and
future
research
Any who
apply
PI Yes Blanket
consent
Samples
destroyed but
not info that has
been used
None US Genetic basis
of cancer
None No, will re-
contact
Follow up
info
Any who
apply
PI Yes Blanket
consent
Samples
destroyed but
not info that has
been used
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sonal identifiers to information generated from research.
Despite these confidentiality measures, twenty-one of
the documents, predominantly those from North Amer-
ica, stated the danger of information of research partici-
pation and even individual results becoming known, and
noted potentially associated repercussions, such as dis-
crimination, as a risk of providing samples. Nine docu-
ments did not specify such socio-economic factors as a
risk of participation in research, while one left the ‘risks’
section blank, to be filled in at the time of use.
Nine of the documents provided potential subjects
with the choice to be re-contacted. In five cases this was
to obtain follow-up health and demographic informa-
tion, in one case to solicit participation in future
research studies, and in three cases for both follow-up
and future studies. Eleven of the documents stated sim-
ply that participants would be re-contacted; six for fol-
low-up information, two to return individual results,
one for both follow-up information and future studies,
and two for both future studies and to return individual
research results. Ten of the documents did not refer to
re-contacting research participants.
Ten of the documents collected stated that general
study results would be made available to participants.
Of those ten, one stated that individual results would
also be returned, one provided participants with a
choice in obtaining individual results, seven stated that
no individual results would be returned, and one did
not discuss individual results. Of the remaining twenty,
four stated that individual results would be returned,
four provided participants with a choice regarding the
return of individual results, nine stated that individual
results would not be returned, and three did not discuss
this issue.
Finally, we looked at the documents’ explanation of
subjects’ ability to withdraw from research participation.
Two documents did not refer to the option to withdraw.
Of the remaining twenty-eight, three stated that should
subjects choose to withdraw, all samples would be
destroyed and information removed from the research
project. Twenty stated that upon withdrawal samples
would be destroyed, but information that had already
been incorporated into research would not be removed.
One document stated that as no identifying information
would be collected, withdrawal would not be possible.
The remaining four documents described participants’
right to withdraw from research, but were ambiguous
about what effect this would have on samples and data.
Discussion
Informed consent in a research context is an autono-
mous action by a subject that authorizes a professional
to involve that subject in a particular research endeavor
[5]. To facilitate this authorization, IC forms must
describe the purpose and scope of the study, potential
risks and benefits of participation, how issues of privacy
and confidentiality will be addressed, whether samples
and/or data will be available to other researchers and
whether research results will be available to participants
and/or the public [6]. General information on informed
consent can be found in guidance documents such as
the United Nations’ Ethical, Social, and Cultural Organi-
zations’“ Universal Declaration on the Human Genome
and Human Rights” (1997) and the Council for Interna-
tional Organization of Medical Sciences’“ Ethics and
Research on Human Subjects: International Guidelines”
(1992). Examining how these issues are addressed in IC
forms that are being used in current cancer genome
sequencing research however provides a more up-to-
date and informative illustration of how investigators in
this domain are balancing their ethical obligations to
research subjects with the ultimate goal of research,
which is to produce generalizable scientific knowledge
for the benefit of society at large [7].
Obtaining Informed Consent for Future Research and
Data Sharing
The goal of large-scale genome sequencing projects is to
create databases of genomic and phenotypic information
to be widely disseminated in support of research
advances [8]. Maximizing the utility of these databases
by making as much information available to as many
researchers as possible is undoubtedly beneficial to the
advancement of science and so to the public good. This
is especially true when databases are linked to identifi-
able and regularly updated personal information, such
as medical records, so that correlations between genetic
factors, treatment strategies and health outcomes can be
made [6]. Broad consent from participants enables the
future application of data to novel contexts that are not
foreseeable at the time of collection [9]. The IC forms
collected for this study illustrate a trend towards the
broad sharing of samples and data, as 73% of the forms
articulated the intention to use the samples for future,
possibly unrelated research and 90% expressed the
intention to share their research data with other, possi-
bly unaffiliated, researchers. However, this otherwise
laudable strategy must be balanced with ethical and
legal obligations to obtain adequately informed consent
from individual participants [6].
The broad data sharing through publicly accessible
databases that is occurring in the context of large scale
sequencing studies presents a challenge to the tradi-
tional conception of informed consent. At the point of
sample collection, neither the researchers who will
request access to the data nor the research questions
that will be asked can be fully predicted [10]. This is
Allen and Foulkes BMC Medical Ethics 2011, 12:14
http://www.biomedcentral.com/1472-6939/12/14
Page 5 of 9especially true considering the extended period of time
for which samples are being maintained and the rapid
rate at which technology is advancing. Consent that is
broad enough to cover all of the potential, unknown
future of uses of research data is arguably too broad to
be meaningful [8]. As a result of this, there is a growing
body of literature in biomedical journals calling for a re-
conceptualization of the role of autonomy and informed
consent in research in order to accommodate the needs
of science. Proponents argue that these databases are a
revolutionary platform for medical research, and can
exist only by relying on models of open consent and
public data access [9]. Obtaining broad consent to mul-
tiple purposes of research and future consent to as yet
unspecified research, as the majority of the forms we
collected did, is therefore being proposed as a legitimate
mechanism for the advancement of science [11].
The Unites States federal research regulations, referred
to as 45CFR46, do not consider research involving only
coded private information or specimens to involve
human subjects, and so does not require informed con-
sent for such research (45CFR46.102(f)). Thirteen of the
forms we examined stated that researchers would not
have access to the codes linking data to individuals, and
so research arising from data sharing in these cases falls
into this category. That being said, there are a number
of reasons to advocate for stronger subject protections
in relation to genomic databases. Especially when geno-
typic data are linked to regularly updated phenotypic
data, which many argue is an essential feature of these
databases [6], there is a risk that even de-identified
sequence data can be matched against third party data-
base to effectively re-identify an individual, and so priv-
acy and confidentiality cannot be guaranteed [12].
Additionally, as WGS data becomes amenable to the
study of complex traits beyond disease, such as beha-
viour, there may be significant risk to both individual
autonomy and cultural identity [8]. Most research ethics
guidelines, including the Declaration of Helsinki, agree
that the objectives of science should not supersede indi-
vidual rights. As the control over information that
implicates personal integrity is recognized as a funda-
mental human right [6], the role of open-access geno-
mic databases in advancing medical research alone is
insufficient to trump the ethical obligation to obtain
truly informed consent. The tension between individual
and social interests in this context therefore remains a
hotly debated issue [13].
Genetic Research and Socio-economic Risk
Ensuring that potential research participants are provid-
ing consent that is substantially informed requires that
the foreseeable risks and benefits of research are fully
disclosed. These include the risk that an individual’s
participation in WGS research and resulting genetic
information could become known to unauthorized par-
ties. While all of the documents we collected stated that
personal identifiers would be removed from samples
and data so as to protect individual privacy, 70% of the
forms also warned potential subject that privacy and
confidentiality measures were not infallible. As each
individual’s genomic code is unique, knowledge of even
a small number of genetic variants can result in samples
being matched to individuals with a relatively high level
of confidence [14]. Even when research data are de-
identified, the increasing linking and interoperability of
various health information databases heightens the pos-
sibility that individuals may be re-identified [15]. The
ease with which research data can be disseminated via
the internet increases the possibility that such informa-
tion may be obtained by entities not subject to privacy
regulations [14]. It is therefore appropriate for research-
ers to warn potential participants that privacy and confi-
dentiality cannot be guaranteed [9]. What is less clear,
however, is what dangers the potential disclosure of
individual genetic information presents.
There has been much concern regarding the potential
misuse of genetic information in the bioethics literature,
not to mention in popular culture. However, little evi-
dence of such discrimination actually occurring has
been documented [16]. That being said, genetic infor-
mation does possess some traits that when considered
collectively, imply that individuals ought to be wary of
sharing their genetic informat i o n .F i r s t l y ,g e n o m i cd a t a
are immutable; other than a relatively small number of
somatic mutations, an individual’s DNA sequence does
not markedly change over time. Given unforeseeable
technological and interpretational advances, particularly
in terms of understanding the genotypic-phenotypic
relationship, this means that public disclosure may have
long lasting and unanticipated effects. Secondly, genetic
information is predictive. While it is ultimately the
gene-environment interaction that will determine what
genetic predispositions manifest, unjust discrimination
may occur on the basis of such future possibilities [14].
Thirdly, genetic data can provide potentially sensitive
information not only about an individual, but about
genetically-related family members and thus familial
r e l a t i o n s h i p sa sw e l l[ 1 7 ] .T h i sa r g u a b l yi n c r e a s e st h e
burden on each individual to protect their genetic infor-
mation: it is not only their own privacy but also that of
their relatives that is at stake. The risk of genetic discri-
mination is likely small, especially as in many countries
there are laws in place to protect individual privacy [18].
However, researchers ought to articulate the potential
dangers associated with individual data entering the
public domain when discussing the risks of participating
in research with their potential subject.
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Results
The forms we collected discussed re-contacting for three
purposes; to suggest further research participation, to
obtain further information about participants, and to
return individual research results. While some commen-
tators argue that re-contacting participants is unduly
burdensome in terms of the time and resources it con-
sumes [19], it can also provide valuable information.
One of the greatest challenges that genetic research cur-
rently faces is elucidating the gene-environment interac-
tions that contribute to health outcomes and so
contacting participants to update this information may
be invaluable to research [20,21]. Investigators must
consider however that particularly in the context of can-
cer genome sequencing, participants may not wish to be
re-contacted. All of the documents we examined
requested samples of tissue that was being removed for
treatment purposes regardless of participation in
research. Tumor removal surgery can obviously be a
stressful time for patients and their families and even
those who agree to have their samples used in research
may not want to be reminded of this period through re-
contacting. Nine of the forms we analyzed provided par-
ticipants with a choice as to whether they wanted to be
re-contacted; researchers should consider providing
such an option if they would like to re-contacting their
participants.
Re-contacting participants in order to return indivi-
dual results is an issue that has recently been highly
debated in the literature. Some argue that individual
results should only be returned if they have clear clinical
utility, and as the contribution of genetics to disease is
still fairly rudimentary, the danger of returning unsub-
stantiated or even inaccurate results outweighs the ben-
efits of returning results that are believed to be valid
[22]. Furthermore, returning individual results may pro-
mote a therapeutic misconception, where the subject
believes that the primary aim of the research is to
advance their own best interests, rather than generate
generalizable knowledge [23]. Additionally, in order to
disclose individual results responsibly, participants must
have access to genetic counselors who can explain to
them the implications of their results, as well as to
necessary follow up treatment [24]. Commentators
argue that these requirements place too great a burden
on the research endeavor [25]. Finally, cancer genome
sequencing poses a particular difficulty in this respect,
as the disease is caused by somatic mutations that may
occur in a multitude of locations. Researchers sequen-
cing cancer genomes are generally not seeking germline
susceptibility loci, as is the case in research on other
genetic diseases. The wide breadth of investigation to
identify the point of carcinogenesis however may well
identify such susceptibility loci incidentally. The issue of
how to manage such incidental results is controversial
[26], but was not mentioned in any of the forms we
collected.
Despite these arguments, in recent years there has
been growing consensus that researchers have an ethical
obligation to return individual research results [27].
Arguments based in such fundamental ethical principles
as respecting participant autonomy, beneficence and
reciprocity, in conjunction with the scientific advances
that are making it increasingly feasible for research to
produce analytically valid and clinically useful results,
substantiate this claim [28]. In addition, providing parti-
cipants of large-scale genomic studies with the option to
receive individual results promises to improve public
understanding of genetics [2 9 ] ,w h i c hi nt u r nm a yh e l p
to reduce the risk of genetic discrimination. Researchers
ought to consider these arguments when designing their
research protocols. One third of the forms we collected
provided participants with individual results or the
option to obtain them, which indicates that doing so is
a feasible endeavor in this context.
Withdrawing from Research
Withdraw from research is generally considered to be a
fundamental right [30,31]. People’s perceptions change
over time, and so this is especially important in long-
term studies [10]. Of the documents we collected, only
two did not discuss this right. An issue that arises here
is the difficulty of removing an individual’s samples and
data from the research project if they have already been
shared with other researchers and/or analyzed and
incorporated into aggregate results. Twenty of the forms
we collected acknowledged this by stating that should
the subject chose to withdraw, their samples would be
destroyed but data already in use would not be removed.
In response to this problem anonymization has been
suggested as an alternative to withdrawing, particularly
so that samples and data can continue to be used in
long-term studies. This is an imperfect solution how-
ever, as samples would no longer be useful for diagnos-
tics, the characterization of group members would not
be prevented, and samples could potentially still be re-
identified [10]. A second suggestion is that in an
attempt to preserve the usefulness of samples, research-
ers could provide participants with withdrawal options.
For example participants could withdraw from further
contact and linkage of their samples with health records,
but continue to allow use of samples and data, as
opposed to withdrawing permission for future use of
samples all together [17]. More research and considera-
tion is required to address this contentious issue, but in
the meantime, researchers ought to make it clear to
subjects that once samples have been analyzed and data
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will be impossible to effect a meaningful retraction at a
later date [9].
Conclusion
This study illustrates that there is a high degree of simi-
larity in how cancer researchers engaged in WGS are
protecting participant privacy and also there is a strong
trend towards both using samples for additional, unspe-
cified research and sharing data with other researchers.
I Cf o r m sw e r em o r ev a r i e di nt e r m so fh o wt h e yd i s -
cussed re-contacting participants, returning results, and
facilitating participant withdrawal from research. While
this variability might arise as a result of differences in
local ethics review board requirements, the research
ethics literature makes a number of recommendations
in respect to these issues, which if taken into considera-
tion may facilitate a degree of standardization across
studies.
Some limitations of this study include that restricting
our analysis to the examination of IC documents means
that some relevant ethical issues, such as for example
participant recruitment, the selection of research ques-
tions, and potential conflicts of interest, could not be
addressed.
Additionally, while WGS is a relatively new technol-
ogy, we compared forms across a period of eight years.
However, as no particular trends seem to emerge over
time, our conclusion that the IC forms vary in a number
of respects is clearly not a reflection of the time period
chosen. It is also worth noting that while we focused on
WGS that is occurring as a part of cancer research stu-
dies in order to facilitate comparison, the majority of
the documents we analyzed were seeking consent for
broader research. As a result of this, our results are
highly generalizable to other studies involving WGS.
As WGS has the advantage of identifying effectively all
genetic changes (i.e. mutation, rearrangement and copy
number) in a genome, it is quickly becoming the ‘gold
standard’ of genetic analysis [32]. However, while the
technology is advancing at a rapid pace, challenges to its
implementation (i.e. to “clinical-grade genomic sequen-
cing”) remain. WGS produces a huge amount of infor-
mation; development of computational analysis and
storage techniques through advances in bioinformatics
is required in order to manage these data. Advances in
our currently limited knowledge of the functional signif-
icance of many human genes, as well as in our under-
standing of gene-environment interactions, are also
needed before the full value of WGS can be realized
[33]. Finally, ELS issues associated both with WGS
research and the implementation of WGS in clinical
care must be addressed if this research is to proceed in
such a way as to both maximize the social good, and
simultaneously respect the rights of participants.
We hope that efforts to generate IC forms that can be
generalizable across jurisdictions will be aided by the-
matic analyses such as the one conducted here.
Additional material
Additional file 1: Summary of published cancer genome sequencing
projects. Provides information on notable cancer genome sequencing
projects that have been published.
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